Healthcare / Drug Manufacturers - Specialty & GenericCanadian Sec
$0.03
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-17.7M · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$14M
P/E
N/A
•EV/EBITDA
N/A
•ROE
30.1%
↑Gross Margin
34.8%
↓Debt/Equity
-1.85
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-9.6%
FCF CAGR
—
FCF margin
-19.4%
FCF / Net income
0.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $64.8M · net income $-68.4M · FCF $-12.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $64.8M | $64.8M | $80.2M | $69.6M | $87.7M |
| Net Income | $-68.4M | $-68.4M | $-26.2M | $-139.7M | $-246.6M |
| EBITDA | $-74.1M | $-74.1M | $20.1M | $8.9M | $-230.6M |
| EPS | — | — | -0.06 | -0.09 | -0.60 |
| Gross Margin | 34.8% | 34.8% | 35.5% | 36.0% | 25.8% |
| Operating Margin | -21.0% | -21.0% | -9.3% | 2.6% | -10.0% |
| Net Margin | -105.5% | -105.5% | -32.7% | -200.8% | -281.2% |
| Balance Sheet | |||||
| Debt/Equity | -1.85 | -1.85 | -2.07 | -2.11 | 9.65 |
| Current Ratio | 0.78 | 0.78 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.6M | $-12.6M | $-17.7M | $-80.8M | $-27.4M |
| Returns | |||||
| ROE | 30.1% | 30.1% | 15.1% | 113.9% | -1242.1% |
| Valuation | |||||
| EV/EBITDA | — | — | 18.53 | 30.96 | — |
| P/B | — | — | — | — | 2.27 |
| Growth & Yield | |||||
| Revenue Growth | -19.1% | -19.1% | 15.2% | -20.7% | — |
| EPS Growth | — | — | 38.1% | 85.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.06 → n/d
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.